Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease

Divya Ayyala, Thomas Bottyan, Christine Tien, Michael Pimienta, Jennie Yoo, Kelli Stager, Jose Luis Gonzalez, Andrew Stolz, Jennifer L. Dodge, Norah A. Terrault, Hyosun Han – 24 October 2022 – Naltrexone is an approved drug for management of alcohol use disorder (AUD), but data in patients with liver disease (LD) are limited. We aimed to evaluate the safety of naltrexone in those with LD. This is a retrospective cohort of adults with and without LD who were prescribed naltrexone for AUD from 2015 to 2019 in a safety‐net setting.

Outcomes of subjects who are lean, overweight or obese with nonalcoholic fatty liver disease: A cohort study in China

Yanqi Lan, Ying Lu, Jinfeng Li, Shiqi Hu, Shuohua Chen, Yanhong Wang, Xiaojie Yuan, Hongmin Liu, Xiaomo Wang, Shouling Wu, Li Wang – 24 October 2022 – The ability to determine the prognosis of lean nonalcoholic fatty liver disease (NAFLD) is essential for decision making in clinical settings. Using a large community‐based Chinese cohort, we aimed to investigate NAFLD outcomes by body mass index (BMI). We used the restricted cubic splines method to investigate the dose–response relationship between BMI and outcomes in subjects with NAFLD and those without NAFLD.

Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single‐blind, placebo‐controlled study in F2/F3 NASH

Stephen A. Harrison, Patrick R. Mayo, Todd M. Hobbs, Carlos Canizares, Erin P. Foster, Caroline Zhao, Daren R. Ure, Daniel J. Trepanier, Jill A. Greytok, Robert T. Foster – 21 October 2022 – Rencofilstat (RCF) demonstrated antifibrotic effects in preclinical models and was safe and well tolerated in Phase 1 studies. The aim of this Phase 2a study was safety, tolerability, pharmacokinetics, and exploration of efficacy biomarkers in subjects with nonalcoholic steatohepatitis (NASH).

Profiling of cell‐free DNA methylation and histone signatures in pediatric NAFLD: A pilot study

Diana Buzova, Maria Rita Braghini, Salvatore Daniele Bianco, Oriana Lo Re, Marco Raffaele, Jan Frohlich, Antoniya Kisheva, Annalisa Crudele, Antonella Mosca, Maria Rita Sartorelli, Clara Balsano, Jan Cerveny, Tommaso Mazza, Anna Alisi, Manlio Vinciguerra – 19 October 2022 – Nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in children and adolescents, increasing the risk of its progression toward nonalcoholic steatohepatitis (NASH), cirrhosis, and cancer.

Subscribe to